Haduvio Opportunity Positions Trevi (TRVI) for Multibagger Gains, Says Morgan Stanley

Trevi Therapeutics Inc. (NASDAQ:TRVI) is one of the best multibagger stocks to invest in right now. On August 21, Morgan Stanley’s Judah Frommer initiated coverage of the stock with an Overweight rating and an $18 price target. The Overweight call is based on Haduvio, the company’s extended-release formulation of nalbuphine, which is being developed as a treatment for chronic cough.

Frommer said Haduvio stands out in a market where existing therapies either offer limited benefit or pose risks such as abuse and respiratory complications. He highlighted its potential to meet a large unmet need for patients with persistent cough.

The analyst estimates that Haduvio could become a multi-billion-dollar opportunity for Trevi Therapeutics Inc. (NASDAQ:TRVI), with growing interest in the pharmaceutical industry adding further support. Large-cap peers such as GSK and Merck have already committed to billion-dollar partnerships in the chronic cough space, suggesting Trevi Therapeutics Inc. (NASDAQ:TRVI) could benefit from heightened attention and investment.

Trevi Therapeutics Inc. (NASDAQ:TRVI) is a clinical-stage biopharmaceutical company developing Haduvio to help patients suffering from chronic cough.

While we acknowledge the potential of TRVI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Most Shorted Stocks Right Now and 10 Best High Beta Stocks To Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.